drugset / Trial / NCT02006147
Phase 1 Open-label Study to Evaluate Efficacy and Tolerability of TLC399 in Patients With Macular Edema Due to RVO
Non-randomizedSequentialOpen-labelTreatment
Summary
To determine whether TLC399 (ProDex) provides an ideal, safe, long-acting, dexamethasone sodium phosphate (DSP) delivery system for the treatment of macular edema due to retinal vein occlusion (RVO).
Timeline
- Start
- 2014-11
- Primary completion
- 2020-07-15
- Completion
- 2020-07-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dexamethasone | Small molecule | 0.24 mg | — |
| Subject | Dexamethasone | Small molecule | 0.36 mg | — |
| Subject | Dexamethasone | Small molecule | 0.6 mg | — |